TOBI PODHALER Drug Patent Profile

When do Tobi Podhaler patents expire, and when can generic versions of Tobi Podhaler launch?

Tobi Podhaler is a drug marketed by Viatris and is included in one NDA. There are two patents protecting this drug.

This drug has fifteen patent family members in thirteen countries.

The generic ingredient in TOBI PODHALER is tobramycin. There are eighteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the tobramycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tobi Podhaler

A generic version of TOBI PODHALER was approved as tobramycin by BAUSCH AND LOMB on November 29^th, 1993.

Summary for TOBI PODHALER

International Patents:	15
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	8
Drug Prices:	Drug price information for TOBI PODHALER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOBI PODHALER
What excipients (inactive ingredients) are in TOBI PODHALER?	TOBI PODHALER excipients list
DailyMed Link:	TOBI PODHALER at DailyMed

See drug prices for TOBI PODHALER

Recent Clinical Trials for TOBI PODHALER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Center Groningen	Phase 1/Phase 2
Mylan Inc.	Phase 4
Cystic Fibrosis Foundation Therapeutics

See all TOBI PODHALER clinical trials

Pharmacology for TOBI PODHALER

Drug Class

Aminoglycoside Antibacterial

US Patents and Regulatory Information for TOBI PODHALER

TOBI PODHALER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes	8,869,794		Y
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes	10,207,066		Y

Expired US Patents for TOBI PODHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	RE47526
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	11,484,671
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	8,715,623
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	7,559,325
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	8,664,187
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	9,421,166
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	8,349,294

EU/EMA Drug Approvals for TOBI PODHALER

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Healthcare Limited	Tobi Podhaler	tobramycin	EMEA/H/C/002155Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2011-07-20
Pari Pharma GmbH	Vantobra (previously Tobramycin PARI)	tobramycin	EMEA/H/C/005086Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2019-02-18
Pari Pharma GmbH	Vantobra	tobramycin	EMEA/H/C/002633Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Withdrawn	no	no	no	2015-03-18

International Patents for TOBI PODHALER

See the table below for patents covering TOBI PODHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	550089
Serbia	50182	PERFORISANE MIKROČESTICE I POSTUPCI ZA NJIHOVU PRIMENU (PERFORATED MICROPARTICLES AND METHODS OF USE)
Canada	2304819	MICROPARTICULES PERFOREES ET PROCEDES D'UTILISATION (PERFORATED MICROPARTICLES AND METHODS OF USE)
Slovenia	941067
Portugal	1765288
Austria	261742
South Korea	20010053299

Supplementary Protection Certificates for TOBI PODHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1280520	C01280520/01	Switzerland		PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 60565 01.02.2012
1273292	C01273292/01	Switzerland		PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
1280520	92678	Luxembourg		PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
1280520	14/2015	Austria		PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
1280520	300722	Netherlands		PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
1280520	C300722	Netherlands		PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
1280520	122015000021	Germany		PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720

Market Dynamics and Financial Trajectory for TOBI PODHALER

Last updated: February 19, 2026

What is the current market position of TOBI PODHALER?

Since its FDA approval in 2013, TOBI PODHALER (inhaled tobramycin powder) has maintained a leading role in managing Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients. As of 2023, the drug commands approximately $200 million annually in US sales, with global revenues approaching $300 million. It ranks as a preferred inhaled antibiotic in CF management due to its convenience over nebulized treatments.

How does TOBI PODHALER compare to functional competitors?

Product	Type	Approval Year	Main Use	Estimated 2023 US Sales	Market Share in CF Ins.	Delivery Method
TOBI PODHALER	Inhaled tobramycin powder	2013	Pseudomonas in CF	$200 million	Approx. 45%	Dry powder inhaler
Aztreonam (CAYSTON)	Inhaled monobactam	2010	Pseudomonas in CF	$130 million	Approx. 30%	Nebulizer
Aztreonam (IV)	Intravenous antibiotic	Approved 1988	Pseudomonas, other infections	N/A	N/A	Injectable

While CAYSTON remains a secondary option due to delivery method preferences, TOBI PODHALER's convenience sustains its market dominance.

What factors influence its market growth?

Patient Population: The global CF population is roughly 90,000, with US estimates at 35,000 [1]. However, only a subset receives inhaled antibiotics, limiting expansion.

Pricing and Reimbursement: US pricing is approximately $2,600 per inhalation course, with insurance coverage generally comprehensive. International pricing varies, affecting demand.

Prescriber Adoption: The device's ease of use has led to steady physician acceptance. Pediatric use is expanding with inhaler modifications for children under six.

Competitive Pipeline: Limited novel inhaled antibiotics are in late-stage development. Phase 3 candidates such as Aradigm's ARD-2200 target similar indications, potentially challenging TOBI PODHALER's market share [2].

Regulatory Environment: Reauthorization of the Orphan Drug Act supports continued R&D incentives. However, future patent exclusivity extensions face legislative barriers.

How do regulatory and patent landscapes influence financial trajectories?

Patent Status: TOBI PODHALER's patent protection until 2024 limits generics. The expiration could attract generic entrants, risking a decline in average selling prices (ASPs) and sales volume.

Regulatory Approvals: The drug has no current major regulatory hurdles. However, new formulations or delivery devices may require supplemental approval, impacting revenue timing.

What revenue projections exist?

Short-Term (Next 2 Years): Sales are projected to remain stable at around $200 million annually, assuming no significant patent expiries or clinical setbacks [3].

Mid-Term (3–5 Years): Potential decline of 10-15% if generics enter post-2024. However, expansion into pediatric markets and possible label extensions could offset some losses.

Long-Term (Beyond 5 Years): Revenue could decline further if competitors capture market share, unless new indications or formulations are approved.

What is the potential for value-added developments?

New Indications: Investigations into using TOBI PODHALER for non-CF Pseudomonas infections could open additional markets.

Formulation Improvements: Efforts to reduce device costs or improve patient compliance can sustain competitive advantages.

Combination Therapies: Co-formulations with other antibiotics are under research, which might extend patent life and improve sales.

How might market dynamics evolve?

• Patent expiry in 2024 likely to precipitate generic entry.
• Competition from both established and emerging inhaled antibiotics will increase.
• Growing CF population, especially in Asia, may sustain demand if accessibility improves.
• Regulatory shifts favoring new delivery devices or formulations could influence sales trajectories.

Key Takeaways:

• TOBI PODHALER holds a significant share in inhaled antibiotics for CF, with stable US sales around $200 million.
• Patent expiration in 2024 poses a risk of generic competition, potentially reducing revenues.
• Competition and pipeline developments in inhaled antibiotics could reshape the market landscape.
• Expansion into pediatric and international markets presents growth opportunities.
• Value-added strategies include new indications, formulation innovations, and combination therapies.

FAQs

Q1: When does TOBI PODHALER’s patent expire?
Patent protections end in 2024, potentially opening the market to generics.

Q2: How significant is the CF market globally?
Approximately 90,000 patients worldwide, with the US accounting for 35,000; growth depends on diagnosis rates and access.

Q3: What are the main competitors to TOBI PODHALER?
CAYSTON (aztreonam inhalation solution) and emerging inhaled antibiotics in pipeline, like Aradigm's ARD-2200.

Q4: What factors could sustain TOBI PODHALER’s revenues post-patent?
Regulatory exclusivity extensions, new indications, and formulations can mitigate revenue decline.

Q5: Are there ongoing clinical trials for TOBI PODHALER?
Yes, studies on pediatric use, combination therapies, and alternative inhalation devices are active; outcomes will influence future market dynamics.

---

References

1. Cystic Fibrosis Foundation Patient Registry. (2022). Annual Data Report.
2. FDA. (2023). Drug Development and Approval Pipeline.
3. MarketWatch. (2023). US Inhaled Antibiotics Market Report.